DE60239450D1 - Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonisten - Google Patents
Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonistenInfo
- Publication number
- DE60239450D1 DE60239450D1 DE60239450T DE60239450T DE60239450D1 DE 60239450 D1 DE60239450 D1 DE 60239450D1 DE 60239450 T DE60239450 T DE 60239450T DE 60239450 T DE60239450 T DE 60239450T DE 60239450 D1 DE60239450 D1 DE 60239450D1
- Authority
- DE
- Germany
- Prior art keywords
- antagonist
- treating psoriasis
- antibody
- il17d29
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000005557 antagonist Substances 0.000 title abstract 3
- 102100033096 Interleukin-17D Human genes 0.000 title 1
- 108010066979 Interleukin-27 Proteins 0.000 title 1
- 201000004681 Psoriasis Diseases 0.000 title 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 abstract 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26421901P | 2001-01-25 | 2001-01-25 | |
| PCT/US2002/002244 WO2002102411A2 (en) | 2001-01-25 | 2002-01-24 | Method for treating psoriasis by using an il-17d antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60239450D1 true DE60239450D1 (de) | 2011-04-28 |
Family
ID=23005084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60239450T Expired - Lifetime DE60239450D1 (de) | 2001-01-25 | 2002-01-24 | Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonisten |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20070048318A1 (de) |
| EP (2) | EP2366406A1 (de) |
| AT (1) | ATE501730T1 (de) |
| AU (1) | AU2002326285A1 (de) |
| CA (1) | CA2435151A1 (de) |
| DE (1) | DE60239450D1 (de) |
| ES (1) | ES2360481T3 (de) |
| WO (1) | WO2002102411A2 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7422743B2 (en) | 2000-05-10 | 2008-09-09 | Schering Corporation | Mammalian receptor protein DCRS5;methods of treatment |
| US20050287593A1 (en) | 2004-05-03 | 2005-12-29 | Schering Corporation | Use of cytokine expression to predict skin inflammation; methods of treatment |
| US7501247B2 (en) | 2004-05-03 | 2009-03-10 | Schering Corporation | Method of treating skin inflammation |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| CA2669267A1 (en) * | 2006-11-08 | 2008-05-15 | Zymogenetics, Inc. | Methods of using transforming growth factor beata-9 |
| US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
| KR102617833B1 (ko) | 2016-05-06 | 2023-12-27 | 엑시큐어 오퍼레이팅 컴퍼니 | 인터류킨 17 수용체 mRNA의 특이적 녹다운을 위한 안티센스 올리고뉴클레오티드 (ASO)를 제시하는 리포좀성 구형 핵산 (SNA) 구축물 |
| US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6610526B2 (en) * | 1998-03-13 | 2003-08-26 | Inctye Corporation | Human E1-like protein |
| JP2002516103A (ja) * | 1998-05-29 | 2002-06-04 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | インターロイキン２１およびインターロイキン２２ |
| US20040132136A1 (en) * | 1998-09-17 | 2004-07-08 | Zymogenetics, Inc. | Mammalian Transforming growth factor beta-9 |
| EP1897948A1 (de) * | 1998-09-17 | 2008-03-12 | ZymoGenetics, Inc. | Säugetier-Umwandlungswachstumsfaktor Beta 9 |
| US20070256145A1 (en) * | 1998-09-17 | 2007-11-01 | Presnell Scott R | Mammalian transforming growth factor beta-9 |
| AR022237A1 (es) * | 1999-01-11 | 2002-09-04 | Schering Corp | Citoquinas mamiferas purificadas; reactivos y metodos relacionados |
| AR028256A1 (es) * | 2000-03-16 | 2003-04-30 | Amgen Inc | Moleculas similares a receptores il-17 y usos de las mismas |
| US20040115191A1 (en) * | 2002-01-24 | 2004-06-17 | Moore Emma E | Method for treating psoriasis |
| CA2606255C (fr) * | 2005-04-18 | 2013-10-08 | Sc Dicophar | Utilisation de la lecithine comme medicament dans le traitement du psoriasis |
| US9355528B2 (en) | 2013-09-17 | 2016-05-31 | Igt | Gaming system and method for providing a cascading symbol game with shifting symbols between multiple symbol display position matrices |
| TWI616792B (zh) | 2017-05-03 | 2018-03-01 | 友達光電股份有限公司 | 觸控顯示裝置的製造方法 |
-
2002
- 2002-01-24 AU AU2002326285A patent/AU2002326285A1/en not_active Abandoned
- 2002-01-24 ES ES02760986T patent/ES2360481T3/es not_active Expired - Lifetime
- 2002-01-24 CA CA002435151A patent/CA2435151A1/en not_active Abandoned
- 2002-01-24 AT AT02760986T patent/ATE501730T1/de active
- 2002-01-24 WO PCT/US2002/002244 patent/WO2002102411A2/en not_active Application Discontinuation
- 2002-01-24 EP EP10184830A patent/EP2366406A1/de not_active Withdrawn
- 2002-01-24 EP EP02760986A patent/EP1359938B1/de not_active Expired - Lifetime
- 2002-01-24 DE DE60239450T patent/DE60239450D1/de not_active Expired - Lifetime
-
2006
- 2006-10-10 US US11/548,017 patent/US20070048318A1/en not_active Abandoned
-
2007
- 2007-05-24 US US11/753,498 patent/US20070280936A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002102411A3 (en) | 2003-09-18 |
| US20070280936A1 (en) | 2007-12-06 |
| AU2002326285A1 (en) | 2003-01-02 |
| CA2435151A1 (en) | 2002-12-27 |
| EP2366406A1 (de) | 2011-09-21 |
| US20070048318A1 (en) | 2007-03-01 |
| EP1359938A2 (de) | 2003-11-12 |
| ES2360481T3 (es) | 2011-06-06 |
| ATE501730T1 (de) | 2011-04-15 |
| EP1359938B1 (de) | 2011-03-16 |
| WO2002102411A2 (en) | 2002-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE478944T1 (de) | Zytokin ligand zur behandlung von asthma und atemwegsüberreaktivität | |
| DE60130797D1 (de) | Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenose | |
| DE60043957D1 (de) | Verfahren zur Behandlung von Entzündungen | |
| ATE404587T1 (de) | Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen | |
| ATE368095T1 (de) | Verfahren zur herstellung von mitteldistillaten | |
| DE60016461D1 (de) | Verfahren zur behandlung von glassubstraten und glassubstraten zur herstellung von anzeigeschirmen | |
| DE60043308D1 (de) | Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin | |
| ATE392430T1 (de) | Verfahren zur herstellung von dipeptiden | |
| DE60232956D1 (de) | Verfahren zur behandlung von stressbedingten erkrankungen unter verwendung von glucocorticoid-rezepto-spezifischen antagonisten | |
| DE50301171D1 (de) | Verfahren zur chargenweise Beschichtung von Sägedraht | |
| DE60330146D1 (de) | Verfahren zur reinigung von fibrinogen | |
| ATE481101T1 (de) | Verfahren zur behandlung von angstzuständen | |
| DE60019321D1 (de) | Verfahren zum screening von inhibitoren von asp2 | |
| DE60239450D1 (de) | Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonisten | |
| DE602004026253D1 (de) | Verfahren zur Herstellung von Stahlbrammen mit ultra-geringem Kohlenstoffgehalt | |
| DE69921450D1 (de) | Verfahren zur herstellung von behandelter kieselsäure | |
| DE602004025267D1 (de) | Verfahren zur herstellung form i von (s)-(+)- clopidogrelbisulfat | |
| ATE296287T1 (de) | Verfahren zur herstellung von repaglinide | |
| ATE270275T1 (de) | Verfahren zur herstellung von 2-aryl-3-aryl-5- halogen-pyridinen, verwendbar als cox-2 inhibitoren | |
| ATE532620T1 (de) | Vorrichtung und verfahren zum temperieren von vorformlingen | |
| DE60324901D1 (de) | Verfahren zur oberflächenreinigung von verunreinigungen enthaltendem graphit mittels einer nh4f und h2so4 enthaltenden wässrigen lösung | |
| DE50107372D1 (de) | Verfahren zur herstellung von glasfliesen, glasbordüren, glasdekorpaneelen oder dgl. | |
| ATE394360T1 (de) | Verfahren zur verminderung von von der verwendung von fluorphosphitkatalysatoren herruehrenden fluoridverunreinigungen | |
| ATE334174T1 (de) | System und prozess zur reinigung und/oder behandlung von fahrzeugoberflächen | |
| ATE405659T1 (de) | Verfahren zur modulierung von cytokininabhängigen vorgängen in einer pflanze mittels b3-domäne- proteinen |